208233
Description
Mind Map by Emma Jones, updated more than 1 year ago
|
Created by Emma Jones
about 11 years ago
|
|
Hepatitis Treatment
- Hepatitis B
- Pegylated alpha interferon
- Expensive,
contraindications,
side effects
- No resistance
- 48 wks subcutaneous
- eAg+ : low response, high sustained response
- eAg- : high response (60%), low sustained response
- Flu-like,
cytopaenia,
depression
- Expensive,
contraindications,
side effects
- Oral anti-virals:
suppress viral
replication
- Examples
- Lamivudine: no longer used due
to low durability of response
- Adefovir: poor response
durability @5yrs
- Entecavir
- Tenofovir
- Lamivudine: no longer used due
to low durability of response
- Effectiveness:
high response
to treatment,
low retained
response
- Side effects: few
- 1/day indefinitely
- Examples
- Pegylated alpha interferon
- Hepatitis C
- Pegylated alpha
interferon + Ribavirin
- Duration
- Genotypes 1&4: 48 weeks, 45% success
- Genotypes 2&3: 24 weeks, 80% success
- Genotypes 1&4: 48 weeks, 45% success
- Side effects
- Pegylated interferon: fatigue, malaise,
neutropaenia, thrombocytopaenia,
depression, insomnia, weight loss, alopecia
- Ribavirin: pruritis, anaemia, rash, nasal congestion
- Pegylated interferon: fatigue, malaise,
neutropaenia, thrombocytopaenia,
depression, insomnia, weight loss, alopecia
- Contraindications
- Interferon: severe depression, psychosis,
cardiac failure, autoimmune disease, pregnancy
- Ribavirin: renal failure, pregnancy
- Interferon: severe depression, psychosis,
cardiac failure, autoimmune disease, pregnancy
- Duration
- HCV N23/4A inhibitors
- Boceprevir
- Anaemia, dysuguesia
- 68% sustained response
- Anaemia, dysuguesia
- Telaprevir
- Severe rash, anaemia, nausea
- 75% sustained response
- Severe rash, anaemia, nausea
- Clinical use
- Genotype 1 only
- Triple Therapy with IFN/Ribavirin:
reduced tolerance due to
combined side effects
- Genotype 1 only
- Boceprevir
- Pegylated alpha
interferon + Ribavirin
Want to create your own Mind Maps for free with GoConqr? Learn more.